GBIO Generation Bio Co.

17.41
-1.28  -7%
Previous Close 18.69
Open 18.9
52 Week Low 17.74
52 Week High 55.72
Market Cap $990,798,991
Shares 56,909,764
Float 30,206,165
Enterprise Value $711,956,489
Volume 176,762
Av. Daily Volume 229,247
Stock charts supplied by TradingView

Latest News

  1. CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results.

    "We are building a leading non-viral genetic medicine company with the potential to transform treatments within multiple therapeutic areas," said Geoff McDonough, M.D., chief executive officer of Generation Bio. "We continue to advance our closed-ended DNA (ceDNA) and next-generation rapid enzymatic synthesis technologies, and plan to provide data on factor VIII expression in non-human primates for our hemophilia A program by year-end. We also continue to develop our cell-targeted…

    CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and third quarter 2021 financial results.

    "We are building a leading non-viral genetic medicine company with the potential to transform treatments within multiple therapeutic areas," said Geoff McDonough, M.D., chief executive officer of Generation Bio. "We continue to advance our closed-ended DNA (ceDNA) and next-generation rapid enzymatic synthesis technologies, and plan to provide data on factor VIII expression in non-human primates for our hemophilia A program by year-end. We also continue to develop our cell-targeted lipid nanoparticle (ctLNP) delivery platform, and with the data recently presented at the ESGCT Congress, demonstrated a breakthrough for the retinal field, potentially paving the way for a wave of novel retinal therapies."

    Business Highlights

    • Reported Preclinical Data Demonstrating Broad Delivery of ceDNA and mRNA to Photoreceptors Using ctLNP: In October 2021, Generation Bio presented preclinical data at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress showing that sub-retinal delivery of closed-ended DNA using cell-targeted lipid nanoparticle (ctLNP-ceDNA) in rodents demonstrated broad distribution and durable expression that was comparable to that achieved with adeno-associated virus Type 5 (AAV5) (the current standard of delivery) in rodents, and tolerability. These findings support the use of ctLNP-ceDNA to potentially achieve full gene replacement for inherited retinal diseases. Similar results were observed for sub-retinal delivery of mRNA using ctLNP in both rodents and non-human primates. This first-ever demonstration of species translation with comparable tolerability and uniform photoreceptor expression across species using ctLNP suggests ctLNP could be a best-in-class non-viral delivery system for mRNA to the retina, potentially enabling gene editing in the retina.

    Third Quarter 2021 Financial Results

    • Cash Position: Cash, cash equivalents and marketable securities were $398.4 million as of September 30, 2021, compared with $262.3 million as of December 31, 2020.



    • R&D Expenses: Research and development (R&D) expenses were $22.0 million for the quarter ended September 30, 2021, compared to $15.3 million for the quarter ended September 30, 2020.



    • G&A Expenses: General and administrative (G&A) expenses were $9.7 million for the quarter ended September 30, 2021, compared to $5.7 million for the quarter ended September 30, 2020.



    • Net Loss: Net loss was $31.9 million, or $0.56 basic and diluted net loss per share, for the quarter ended September 30, 2021, compared to a net loss of $20.8 million for the quarter ended September 30, 2020.

    About Generation Bio

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platform, our research and clinical development plans, the expected timing of the submission of investigational new drug, or IND, applications and preclinical data, our manufacturing plans, our expectations regarding our new facility and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company's product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the timing and ability to complete the build-out of the company's manufacturing facility and regarding the new manufacturing process; expectations regarding the timing of submission of IND applications; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the company's cash resources are sufficient to fund the company's operating expenses and capital expenditure requirements for the period anticipated; the impact of the COVID-19 pandemic on the company's business and operations; as well as the other risks and uncertainties set forth in the "Risk Factors" section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date on which they were made.

    Contacts:

    Investors

    Maren Killackey

    Generation Bio

    541-646-2420

    Media

    Alicia Webb

    Generation Bio

    847-254-4275

    Lisa Raffensperger

    Ten Bridge Communications

    617-903-8783

    GENERATION BIO CO.

    CONSOLIDATED BALANCE SHEET DATA

    (Unaudited)

    (In thousands)

    Earnings Release Balance Sheet September 30, 2021 December 31, 2020
    Cash, cash equivalents and marketable securities $398,363  $262,327 
    Working capital  388,764   256,515 
    Total assets  464,033   294,155 
    Total stockholders' equity  407,210   268,013 
             

    GENERATION BIO CO.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (in thousands, except share and per share data)

         Three Months Ended September 30, 
         2021    2020
    Operating expenses:      
    Research and development $21,991  $15,308 
    General and administrative  9,667   5,661 
    Total operating expenses  31.658   20,969 
    Loss from operations  (31,658)  (20,969)
    Other (expense) income:      
    Other (expense) and interest income, net  (197)  120 
    Net loss and net loss attributable to common stockholders $(31,855) $(20,849)
    Net loss per share attributable to common stockholders, basic and diluted $(0.56) $(0.46)
    Weighted average common shares outstanding, basic and diluted  56,629,193   45,468,838 
           
    Comprehensive loss:      
    Net loss $(31,855) $(20,849)
    Other comprehensive loss:      
    Unrealized (losses) gains on marketable securities  (3)  30 
    Comprehensive loss $(31,858) $(20,819)
             


    Primary Logo

    View Full Article Hide Full Article
  2. Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potential to address inherited retinal diseases with full gene replacement

    Uniform retinal transduction and tolerability also demonstrated for ctLNP delivery of mRNA following sub-retinal injection in non-human primates; potential best-in-class non-viral delivery of mRNA for gene editing in the retina

    CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented new preclinical data demonstrating widespread…

    Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potential to address inherited retinal diseases with full gene replacement

    Uniform retinal transduction and tolerability also demonstrated for ctLNP delivery of mRNA following sub-retinal injection in non-human primates; potential best-in-class non-viral delivery of mRNA for gene editing in the retina

    CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented new preclinical data demonstrating widespread delivery of multiple nucleic acid cargos to photoreceptors using the company's cell-targeted lipid nanoparticle (ctLNP). The findings were shared in an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Virtual Congress.

    "We're excited to extend the benefits of our highly specific, cell-targeted LNP to the retina, where non-viral delivery of nucleic acids has long been held back by poor tolerability and low expression. Our ability to selectively deliver multiple nucleic acid cargos to the retina using ctLNP may allow us to address a variety of inherited retinal diseases using full gene replacement or gene editing," said Matthew Stanton, Ph.D., chief scientific officer of Generation Bio.  

    Sub-retinal delivery of Generation Bio's proprietary closed-ended DNA (ceDNA) using ctLNP demonstrated broad photoreceptor distribution and durable expression in rodents. Expression was comparable to AAV5 delivery, and ctLNP-ceDNA was well-tolerated without evidence of photoreceptor degeneration, supporting the potential for full gene replacement to address inherited retinal diseases.

    Data were also presented for sub-retinal delivery of mRNA using ctLNP, representing the first-ever demonstration of species translation from rodents to non-human primates with tolerability and uniform photoreceptor expression. Distribution with ctLNP was broader and more uniform than that achieved with AAV5 in mice, and total expression was comparable to AAV5. These findings suggest ctLNP as a best-in-class non-viral delivery system for mRNA, potentially enabling gene editing in the retina.

    "Diseases such as Stargardt cannot be addressed with traditional viral-based genetic therapies due to the limited cargo capacity of the viral vector. We believe these data using our non-viral genetic medicine platform provide a promising path to treat this challenging disease and others like it, and may expand our platform's potential to enable multiple therapeutic modalities, including full gene replacement and gene editing," said Tracy Zimmermann, Ph.D., chief development officer of Generation Bio. "We are excited for the potential for our non-viral delivery technology to expand therapeutic opportunities in the retina as well as to target other tissue types for the treatment of a broad range of diseases."

    To view the digital presentation, please visit Generation Bio's website.

    About Generation Bio

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platform, our research and clinical development plans, the expected timing of the submission of IND applications and preclinical data, our manufacturing plans, our expectations regarding our new facility and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company's product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the timing and ability to complete the build-out of the company's manufacturing facility and regarding the new manufacturing process; expectations regarding the timing of submission of IND applications; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the company's cash resources are sufficient to fund the company's operating expenses and capital expenditure requirements for the period anticipated; the impact of the COVID-19 pandemic on the company's business and operations; as well as the other risks and uncertainties set forth in the "Risk Factors" section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date on which they were made.

    Contacts:

    Investors

    Maren Killackey

    Generation Bio

    541-646-2420

    Media

    Alicia Webb

    Generation Bio

    847-254-4275

    Lisa Raffensperger

    Ten Bridge Communications

    617-903-8783

     



    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.

    A live webcast of the panel will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.

    About Generation Bio

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent…

    CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.

    A live webcast of the panel will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.

    About Generation Bio

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Contact:

    Investors 

    Maren Killackey

    Generation Bio



    541-646-2420

    Media 

    Alicia Webb

    Generation Bio



    847-254-4275

    Lisa Raffensperger

    Ten Bridge Communications



    617-903-8783



    Primary Logo

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company's retina therapeutic area.

    "We are excited to share our preclinical data demonstrating broad access to key cell types with our lipid nanoparticle developed for the retina," said Matthew Stanton, Ph.D., chief scientific officer of Generation Bio. "Many inherited retinal diseases remain out of reach for viral-based gene therapies due to limited…

    CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company's retina therapeutic area.

    "We are excited to share our preclinical data demonstrating broad access to key cell types with our lipid nanoparticle developed for the retina," said Matthew Stanton, Ph.D., chief scientific officer of Generation Bio. "Many inherited retinal diseases remain out of reach for viral-based gene therapies due to limited cargo capacity. We believe our non-viral delivery technology could overcome this barrier and expand the potential of our genetic medicine platform to treat more diseases."

    The presentation will be streamed online for registered attendees on October 22, and a recording of the presentation will be made available for attendees for 30 days following the event.

    Generation Bio will present:

    • Development of a novel lipid nanoparticle with widespread photoreceptor delivery of ceDNA & mRNA cargos  
      • Presented by Michelle LeBlanc, Friday, October 22, 2021, at 10:30 a.m. CEST (4:30 a.m. ET)

    About Generation Bio

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Contacts:

    Investors

    Maren Killackey

    Generation Bio

    541-646-2420

     

    Media

    Alicia Webb

    Generation Bio

    847-254-4275

    Lisa Raffensperger

    Ten Bridge Communications

    617-903-8783

     

     



    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results.

    "This quarter we announced our shift to rapid enzymatic synthesis, or RES, for production of our closed-ended DNA, ceDNA, constructs and our signing of a lease to establish significant internal current Good Manufacturing Practice, or cGMP, manufacturing capacity. These are important steps toward our goal of extending the reach of our durable, redosable genetic medicines to patients with prevalent diseases," said Geoff McDonough, M.D., chief executive officer of Generation Bio…

    CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results.

    "This quarter we announced our shift to rapid enzymatic synthesis, or RES, for production of our closed-ended DNA, ceDNA, constructs and our signing of a lease to establish significant internal current Good Manufacturing Practice, or cGMP, manufacturing capacity. These are important steps toward our goal of extending the reach of our durable, redosable genetic medicines to patients with prevalent diseases," said Geoff McDonough, M.D., chief executive officer of Generation Bio. "We will continue to advance the platform throughout the rest of the year and expect factor VIII expression data with ceDNA produced using RES in non-human primates for our hemophilia A program by year-end."

    Business Highlights

    • Transition of Portfolio to Next-Generation Rapid Enzymatic Manufacturing Process Underway: In July 2021, Generation Bio announced plans to deploy next-generation RES for manufacturing its closed-ended DNA (ceDNA) constructs across all portfolio programs. The company also signed a lease agreement to build out a state-of-the-art cGMP facility of approximately 104,000 square feet in Waltham, Mass. to scale RES for clinical and initial commercial supply. The facility is expected to be operational in 2023, enabling an Investigational New Drug (IND) application and clinical development for the company's lead program in hemophilia A. The company is using its existing infrastructure for current production of research material using RES. As Generation Bio transitions to RES, it expects to update its program development strategy and timelines for its pipeline.

    Second Quarter 2021 Financial Results

    • Cash Position: Cash, cash equivalents and marketable securities were $425.2 million as of June 30, 2021, compared with $262.3 million as of December 31, 2020.
    • R&D Expenses: Research and development (R&D) expenses were $22.7 million for the quarter ended June 30, 2021, compared to $13.5 million for the quarter ended June 30, 2020.
    • G&A Expenses: General and administrative (G&A) expenses were $8.2 million for the quarter ended June 30, 2021, compared to $4.3 million for the quarter ended June 30, 2020.
    • Net Loss: Net loss was $30.8 million, or $0.55 basic and diluted net loss per share, for the quarter ended June 30, 2021, compared to a net loss of $17.7 million, or $1.50 basic and diluted net loss per share, for the quarter ended June 30, 2020.

    About Generation Bio  

    Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio's manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platform, our research and clinical development plans, the expected timing of the submission of IND applications and preclinical data, our manufacturing plans, our expectations regarding our new facility and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company's product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the timing and ability to complete the build-out of the company's manufacturing facility and regarding the new manufacturing process; expectations regarding the timing of submission of IND applications; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the company's cash resources are sufficient to fund the company's operating expenses and capital expenditure requirements for the period anticipated; the impact of the COVID-19 pandemic on the company's business and operations; as well as the other risks and uncertainties set forth in the "Risk Factors" section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date on which they were made.

    Contacts:

    Investors

    Maren Killackey

    Generation Bio

    541-646-2420

    Media

    Alicia Webb

    Generation Bio

    847-254-4275

    Lisa Raffensperger

    Ten Bridge Communications

    617-903-8783

    GENERATION BIO CO.

    CONSOLIDATED BALANCE SHEET DATA

    (Unaudited)

    (In thousands)

    Earnings Release Balance Sheet June 30, 2021 December 31, 2020
    Cash, cash equivalents and marketable securities $425,193 $262,327
    Working capital  418,810  256,515
    Total assets  490,792  294,155
    Total stockholders' equity  433,402  268,013



    GENERATION BIO CO.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited) 

    (in thousands, except share and per share data)

         Three Months Ended June 30,
         2021  2020 
    Operating expenses:      
    Research and development $22,656  $13,456 
    General and administrative  8,186   4,308 
    Total operating expenses  30,842   17,764 
    Loss from operations  (30,842)  (17,764)
    Other income:      
    Interest income  51   33 
    Net loss and net loss attributable to common stockholders $(30,791) $(17,731)
    Net loss per share attributable to common stockholders, basic and diluted $(0.55) $(1.50)
    Weighted average common shares outstanding, basic and diluted  56,318,025   11,801,704 
           
    Comprehensive loss:      
    Net loss $(30,791) $(17,731)
    Other comprehensive loss:      
    Unrealized losses on marketable securities  (6)  (4)
    Comprehensive loss $(30,797) $(17,735)
             


    Primary Logo

    View Full Article Hide Full Article
View All Generation Bio Co. News